SUBSCRIBE
SUBSCRIBE
News   Policy

FDA Panel to Review Abbott Laboratories’s Meridia on Sept. 15, 2010

August 6, 2010 | 
1 min read
Reuters -- Abbott Laboratories' (ABT.N) weight loss drug Meridia will be reviewed by an advisory panel to the U.S. Food and Drug Administration on September 15, the company said on Friday.
Regulatory
Food and Drug Administration (FDA) Abbott Laboratories
MORE ON THIS TOPIC
Pointing up with fingers number three. Close up, isolated on white background.
Cancer
Replimune gets early August decision date for twice-rejected melanoma drug
June 26, 2026
 · 
3 min read
 · 
Tristan Manalac
Plan to buying new house or renovation, mortgage loan or housing expense, property maintenance or real estate insurance concept, smart businessman put jigsaw to complete or finishing house puzzle.
FDA
BIO 2026: FDA’s IND initiative is a step toward normalization after slipshod year
June 25, 2026
 · 
3 min read
 · 
Jef Akst
Insights
The Golden Triangle and the gaps: Rethinking UK biotech
June 25, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Success to win in business competition, overcome obstacles or motivation to solve problem and lead company achievement concept, confident businessman leader jump high over 3 hurdles to be winner.
Approvals
Ionis secures market expansion for Tryngolza as FDA clears severe hypertriglyceridemia use
June 25, 2026
 · 
2 min read
 · 
Tristan Manalac